Morgan Stanley Call 220 22UA 20.1.../ DE000MB3SJK8 /
2024-04-12 9:50:37 PM | Chg.- | Bid10:00:34 PM | Ask10:00:34 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.101EUR | - | - Bid Size: - |
- Ask Size: - |
BIONTECH SE SPON. AD... | 220.00 - | 2024-12-20 | Call |
GlobeNewswire
04-22
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
GlobeNewswire
04-07
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persis...
GlobeNewswire
03-20
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
GlobeNewswire
03-20
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
GlobeNewswire
03-11
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidat...
GlobeNewswire
03-06
BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update ...
GlobeNewswire
02-08
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...
GlobeNewswire
01-31
BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjuga...
GlobeNewswire
01-22
BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/...
GlobeNewswire
01-09
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
2023-12-21
BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Can...
GlobeNewswire
2023-12-18
BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
GlobeNewswire
2023-11-06
BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update
GlobeNewswire
2023-10-26
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Agains...
GlobeNewswire
2023-10-23
BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advance...
GlobeNewswire
2023-10-23
BioNTech to Report Third Quarter Financial Results and Corporate Update on November 6, 2023, And to ...
GlobeNewswire
2023-10-19
BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial wit...
GlobeNewswire
2023-10-16
BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023